ENLIVEN THERAPEUTICS INC.
NASDAQ: ELVN (Enliven Therapeutics, Inc.)
Last update: 8 hours ago37.32
-2.01 (-5.11%)
| Previous Close | 39.33 |
| Open | 39.33 |
| Volume | 1,188,421 |
| Avg. Volume (3M) | 1,171,850 |
| Market Cap | 2,734,464,768 |
| Price / Book | 3.77 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2026 |
| Diluted EPS (TTM) | -1.92 |
| Total Debt/Equity (MRQ) | 0.23% |
| Current Ratio (MRQ) | 21.07 |
| Operating Cash Flow (TTM) | -73.96 M |
| Levered Free Cash Flow (TTM) | -45.43 M |
| Return on Assets (TTM) | -21.36% |
| Return on Equity (TTM) | -31.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Enliven Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 0.50 |
Select this tab to load the latest available analysis.
|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 4.75% |
| % Held by Institutions | 90.86% |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |